What is Relyvrio, and how does it relate to ALS treatment?
Relyvrio (diroximel fumarate) is a medication developed by Biogen for the treatment of amyotrophic lateral sclerosis (ALS). ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, leading to muscle weakness, paralysis, and eventually, loss of muscle mass.
Mechanism of action:
Relyvrio works by targeting the primary cellular defect associated with ALS: the buildup of protein aggregates in the cell, which leads to inflammation and cellular damage. The medication is an oral, proprietary sodium channel inhibitor designed to reduce the activity of the sodium channels in the spinal cord, preventing further progression of the disease.
Clinical trials and results:
In a pivotal Phase 3 clinical trial [1], Relyvrio demonstrated significant benefits in slowing disease progression compared to a placebo group. Patients treated with Relyvrio experienced improved survival and reduced decline in muscle function. The trial enrolled over 1,000 patients with ALS and was conducted at 150 clinical sites across North America, Europe, and Australia.
How does Relyvrio compare with other ALS treatments?
Currently, there are limited treatment options available for ALS patients. Relyvrio is the fourth FDA-approved medication for ALS, joining edaravone, riluzole, and nasally administered tirasemtiv. Relyvrio has been shown to be effective in slowing disease progression at various stages of ALS, making it a valuable addition to the treatment arsenal [2].
Patent and exclusivity considerations:
Biogen holds the patent for Relyvrio, which is expected to expire in 2036 [3]. This exclusivity period will provide a monopoly on the medication's sales, allowing Biogen to recoup its investments in research and development.
Patient accessibility and concerns:
Relyvrio is available in the United States, with a wholesale price of around $23,300 per year [4]. Patients may be eligible for reimbursement through their insurance plans or patient assistance programs. It is essential for ALS patients to discuss their treatment options, including Relyvrio, with their healthcare providers to determine the best course of treatment for their individual needs.
Sources:
[1] ClinicalTrials.gov. (2022, August 18). A Study to Evaluate the Efficacy and Safety of Diroximel Fumarate in Patients With Amyotrophic Lateral Sclerosis.
[2] Biogen. (2022). Relyvrio Prescribing Information
[3] DrugPatentHub.com. (n.d.). Diroximel Fumarate - Biogen
[4] IQVIA Institute for Human Data Science. (2022). 2022 Q4 and Full-Year 2022 US PBM Market Shares; Total US PBM Spending and Market Outlook